Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6 months prior to first administration of any study agent~* Must be a candidate for phototherapy or systemic treatment for psoriasis (either new to treatment or having had previous treatment)~* Must be considered, in the opinion of the investigator, suitable candidates for adalimumab therapy~* If a woman, she must be postmenopausal, or if premenopausal, she must be either surgically sterile, practicing a highly effective method of birth control, or not heterosexually active during the study and for 5 months after receiving the last dose of study drug~* If a man, he must agree to use a double-barrier method of birth control (or must have been surgically sterilized) and to not donate sperm during the study and for 5 months after receiving the last dose of study drug.~Exclusion Criteria:~* History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease~* Has a contra-indication to anti-TNF therapy~* Has a history of chronic or recurrent infectious disease~* Has a nonplaque form of psoriasis or has drug-induced psoriasis~* Has been previously treated with adalimumab~* Has received any therapeutic agent directly targeted to IL-12, IL-17, or IL-23, (including but not limited to ustekinumab, briakinumab \[ABT-874\], AIN457, and SCH900222) within 6 months of the first administration of study agent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- CNTO 1959 (5 mg) (Type: EXPERIMENTAL): CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
- CNTO 1959 (15 mg) (Type: EXPERIMENTAL): CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
- CNTO 1959 (50 mg) (Type: EXPERIMENTAL): CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
- CNTO 1959 (100 mg) (Type: EXPERIMENTAL): CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
- CNTO 1959 (200 mg) (Type: EXPERIMENTAL): CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
- Adalimumab (approved psoriasis dosing) (Type: ACTIVE_COMPARATOR): Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)
- Placebo to CNTO 1959 (100 mg) (Type: PLACEBO_COMPARATOR): Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40

Based on this trial design, predict the completion outcome and termination type (if applicable).